<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02076100</url>
  </required_header>
  <id_info>
    <org_study_id>8408-003</org_study_id>
    <secondary_id>2013-005094-41</secondary_id>
    <secondary_id>MK-8408-003</secondary_id>
    <nct_id>NCT02076100</nct_id>
  </id_info>
  <brief_title>Safety, Pharmacokinetics, and Pharmacodynamics of Ruzasvir (MK-8408) in Participants With Hepatitis C Infection (MK-8408-003)</brief_title>
  <official_title>A Multiple Dose Study to Evaluate Safety, Pharmacokinetics, and Pharmacodynamics of MK-8408 in Subjects With Hepatitis C Infection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 3-part study of Ruzasvir (MK-8408) for participants with hepatitis C infection.
      Successive participants will be enrolled as dose levels are evaluated to find the maximum
      safe and well tolerated dose of Ruzasvir. Part I will be for participants with hepatitis C
      virus (HCV) genotype 3 (GT3) and will run first: Part II will be for participants with HCV
      genotype 1a (GT1a), and Part III will be for participants with HCV genotype 2b (GT2b). Parts
      II and III may run concurrently. The primary study hypothesis is that a safe and tolerable
      dose of Ruzasvir that reduces viral load will be found to support further clinical
      investigation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 27, 2014</start_date>
  <completion_date type="Actual">November 15, 2015</completion_date>
  <primary_completion_date type="Actual">November 15, 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum log10 HCV Ribonucleic Acid (RNA) Change From Baseline</measure>
    <time_frame>Baseline and up to Day 5</time_frame>
    <description>Blood was collected at baseline and on Days 1, 2, 3, 4 and 5 to determine HCV RNA levels. Least squares means (LSM) and confidence intervals (CI) were obtained from an analysis of variance (ANOVA) model with maximum log10 HCV RNA change from baseline as response and a fixed effect for treatment. The primary hypothesis was that the mean change from baseline would be a reduction of ≥3 log10. A positive change from baseline indicates a reduction from baseline in log10 HCV RNA.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Experienced One or More Adverse Events (AEs)</measure>
    <time_frame>Up to 61 days</time_frame>
    <description>An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants Who Discontinued Study Drug Due To An AE</measure>
    <time_frame>Up to 5 days</time_frame>
    <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">22</enrollment>
  <condition>Hepatitis C Infection</condition>
  <arm_group>
    <arm_group_label>Part I GT3 Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part II GT1a Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part III GT2b Participants</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ruzasvir</intervention_name>
    <description>Ruzasvir capsules, orally, starting at a dose of 60 mg once per day (QD) x 5 days with doses increasing or decreasing as clinically indicated.</description>
    <arm_group_label>Part I GT3 Participants</arm_group_label>
    <arm_group_label>Part II GT1a Participants</arm_group_label>
    <arm_group_label>Part III GT2b Participants</arm_group_label>
    <other_name>MK-8408</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Body mass index (BMI) &gt;=18 to&lt;=37 kg/m^2

          -  In general good health, except for HCV infection

          -  Clinical diagnosis of chronic HCV infection exclusively GT3 (Panels A-D) or
             exclusively GT1a (Panels E-F), or exclusively GT2b (Panels G-H).

          -  Must agree to follow the smoking restrictions defined by the CRU

          -  Must agree to use an acceptable method of contraception during the study and for 90
             days after the last dose of ruzasvir

        Exclusion Criteria:

          -  Clinically significant endocrine, gastrointestinal, cardiovascular, hematological,
             hepatic, immunological, renal, respiratory, genitourinary or major neurological
             abnormalities or diseases

          -  History of clinically significant hepatic disease, Gilbert's disease or biliary tract
             disease

          -  History of cancer (malignancy) with the exception of adequately treated
             non-melanomatous skin carcinoma or carcinoma in situ of the cervix, or
             successfully-treated malignancies ≥10 years prior to screening

          -  History of significant multiple and/or severe allergies or has had an anaphylactic
             reaction or significant intolerability to prescription or nonprescription drugs or
             food

          -  Positive for hepatitis B or human immunodeficiency virus (HIV)

          -  Major surgery or donated or lost 1 unit of blood (approximately 500 mL) within 4 weeks
             prior to screening

          -  Participated in another investigational trial within 4 weeks prior to the screening
             visit

          -  QTc interval &gt;=470 msec (for males) or &gt;= 480 msec (for females)

          -  Unable to refrain from or anticipates use of any medication (prescription and/or
             non-prescription) or herbal remedies beginning approximately 2 weeks prior to first
             study drug dose, throughout the trial until the post-trial visit

          -  Consumes &gt;2 glasses of alcoholic beverages per day

          -  Regular user (including &quot;recreational use&quot;) of any illicit drugs or history of drug
             (including alcohol) abuse within approximately 12 months

          -  Evidence or history of chronic hepatitis not caused by HCV

          -  Previous treatment with other HCV NS5A inhibitors such as MK-8742, daclatasvir, or
             MK-8325

          -  Treatment with other HCV therapies such as the HCV protease

          -  Evidence of advanced or decompensated liver disease; evidence of bridging fibrosis or
             higher grade fibrosis (Metavir score &gt;=3)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <removed_countries>
    <country>Germany</country>
    <country>Moldova, Republic of</country>
    <country>Netherlands</country>
    <country>New Zealand</country>
  </removed_countries>
  <verification_date>December 2018</verification_date>
  <study_first_submitted>February 27, 2014</study_first_submitted>
  <study_first_submitted_qc>February 27, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 3, 2014</study_first_posted>
  <results_first_submitted>April 16, 2018</results_first_submitted>
  <results_first_submitted_qc>November 26, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">November 28, 2018</results_first_posted>
  <last_update_submitted>December 3, 2018</last_update_submitted>
  <last_update_submitted_qc>December 3, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">December 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ruzasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://engagezone.msd.com/doc/ProcedureAccessClinicalTrialData.pdf</ipd_description>
    <ipd_url>http://engagezone.msd.com/ds_documentation.php</ipd_url>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Males or females of non-child bearing potential, with verified Hepatitis C virus (HCV) infection with genotype (GT) GT1a, GT2b or GT3 between the ages of 18 and 65 years (inclusive) were enrolled in this trial. In the GT1a group, one participant was later determined to be GT1b.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Ruzasvir 10 mg - GT3</title>
          <description>GT3 participants were administered 10 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="P2">
          <title>Ruzasvir 30 mg - GT3</title>
          <description>GT3 participants were administered 30 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="P3">
          <title>Ruzasvir 60 mg - GT3</title>
          <description>GT3 participants were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="P4">
          <title>Ruzasvir 120 mg - GT3</title>
          <description>GT3 participants were administered 120 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="P5">
          <title>Ruzasvir 10 mg - GT2b</title>
          <description>GT2b participants were administered 10 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="P6">
          <title>Ruzasvir 60 mg - GT2b</title>
          <description>GT2b participants were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="P7">
          <title>Ruzasvir 60 mg - GT1a</title>
          <description>GT1a participants were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days. One participant was later determined to be GT1b.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="3"/>
                <participants group_id="P5" count="3"/>
                <participants group_id="P6" count="3"/>
                <participants group_id="P7" count="4"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
                <participants group_id="P6" count="0"/>
                <participants group_id="P7" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ruzasvir 10 mg - GT3</title>
          <description>GT3 participants were administered 10 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="B2">
          <title>Ruzasvir 30 mg - GT3</title>
          <description>GT3 participants were administered 30 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="B3">
          <title>Ruzasvir 60 mg - GT3</title>
          <description>GT3 participants were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="B4">
          <title>Ruzasvir 120 mg - GT3</title>
          <description>GT3 participants were administered 120 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="B5">
          <title>Ruzasvir 10 mg - GT2b</title>
          <description>GT2b participants were administered 10 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="B6">
          <title>Ruzasvir 60 mg - GT2b</title>
          <description>GT2b participants were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="B7">
          <title>Ruzasvir 60 mg - GT1a</title>
          <description>GT1a participants were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days. One participant was later determined to be GT1b.</description>
        </group>
        <group group_id="B8">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="3"/>
            <count group_id="B2" value="3"/>
            <count group_id="B3" value="3"/>
            <count group_id="B4" value="3"/>
            <count group_id="B5" value="3"/>
            <count group_id="B6" value="3"/>
            <count group_id="B7" value="4"/>
            <count group_id="B8" value="22"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40.7" spread="6.5"/>
                    <measurement group_id="B2" value="36.0" spread="3.5"/>
                    <measurement group_id="B3" value="38.0" spread="10.4"/>
                    <measurement group_id="B4" value="40.7" spread="13.6"/>
                    <measurement group_id="B5" value="56.3" spread="2.1"/>
                    <measurement group_id="B6" value="54.0" spread="6.2"/>
                    <measurement group_id="B7" value="48.5" spread="6.2"/>
                    <measurement group_id="B8" value="45.0" spread="9.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="1"/>
                    <measurement group_id="B7" value="0"/>
                    <measurement group_id="B8" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="2"/>
                    <measurement group_id="B7" value="4"/>
                    <measurement group_id="B8" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Maximum log10 HCV Ribonucleic Acid (RNA) Change From Baseline</title>
        <description>Blood was collected at baseline and on Days 1, 2, 3, 4 and 5 to determine HCV RNA levels. Least squares means (LSM) and confidence intervals (CI) were obtained from an analysis of variance (ANOVA) model with maximum log10 HCV RNA change from baseline as response and a fixed effect for treatment. The primary hypothesis was that the mean change from baseline would be a reduction of ≥3 log10. A positive change from baseline indicates a reduction from baseline in log10 HCV RNA.</description>
        <time_frame>Baseline and up to Day 5</time_frame>
        <population>Participants who complied with the protocol sufficiently to ensure that generated data would exhibit the effects of treatment, according to the underlying scientific model. Compliance covers considerations such as exposure to treatment, availability of measurements and absence of major protocol violations.</population>
        <group_list>
          <group group_id="O1">
            <title>Ruzasvir 10 mg - GT3</title>
            <description>GT3 participants were administered 10 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Ruzasvir 30 mg - GT3</title>
            <description>GT3 participants were administered 30 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O3">
            <title>Ruzasvir 60 mg - GT3</title>
            <description>GT3 participants were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>Ruzasvir 120 mg - GT3</title>
            <description>GT3 participants were administered 120 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>Ruzasvir 10 mg - GT2b</title>
            <description>GT2b participants were administered 10 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O6">
            <title>Ruzasvir 60 mg - GT2b</title>
            <description>GT2b participants were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>Ruzasvir 60 mg - GT1a</title>
            <description>GT1a participants were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O8">
            <title>Ruzasvir 60 mg - GT1b</title>
            <description>A GT1b participant was administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum log10 HCV Ribonucleic Acid (RNA) Change From Baseline</title>
          <description>Blood was collected at baseline and on Days 1, 2, 3, 4 and 5 to determine HCV RNA levels. Least squares means (LSM) and confidence intervals (CI) were obtained from an analysis of variance (ANOVA) model with maximum log10 HCV RNA change from baseline as response and a fixed effect for treatment. The primary hypothesis was that the mean change from baseline would be a reduction of ≥3 log10. A positive change from baseline indicates a reduction from baseline in log10 HCV RNA.</description>
          <population>Participants who complied with the protocol sufficiently to ensure that generated data would exhibit the effects of treatment, according to the underlying scientific model. Compliance covers considerations such as exposure to treatment, availability of measurements and absence of major protocol violations.</population>
          <units>log10 IU/mL</units>
          <param>Least Squares Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="3"/>
                <count group_id="O8" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.84" lower_limit="1.94" upper_limit="3.74"/>
                    <measurement group_id="O2" value="3.03" lower_limit="2.13" upper_limit="3.94"/>
                    <measurement group_id="O3" value="3.36" lower_limit="2.46" upper_limit="4.26"/>
                    <measurement group_id="O4" value="1.81" lower_limit="0.90" upper_limit="2.71"/>
                    <measurement group_id="O5" value="3.82" lower_limit="3.15" upper_limit="4.50"/>
                    <measurement group_id="O6" value="3.62" lower_limit="2.95" upper_limit="4.30"/>
                    <measurement group_id="O7" value="3.63" lower_limit="2.46" upper_limit="4.81"/>
                    <measurement group_id="O8" value="3.82" lower_limit="NA" upper_limit="NA">Data reflect n=1 and therefore 90% CI was not calculable.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Experienced One or More Adverse Events (AEs)</title>
        <description>An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
        <time_frame>Up to 61 days</time_frame>
        <population>All participants who received at least one dose of the investigational drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Ruzasvir 10 mg - GT3</title>
            <description>GT3 participants were administered 10 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Ruzasvir 30 mg - GT3</title>
            <description>GT3 participants were administered 30 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O3">
            <title>Ruzasvir 60 mg - GT3</title>
            <description>Participants with GT3 were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>Ruzasvir 120 mg - GT3</title>
            <description>GT3 participants were administered 120 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>Ruzasvir 10 mg - GT2b</title>
            <description>GT2b participants were administered 10 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O6">
            <title>Ruzasvir 60 mg - GT2b</title>
            <description>GT2b participants were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>Ruzasvir 60 mg - GT1a</title>
            <description>GT1a participants were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days. One participant was later determined to be GT1b.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced One or More Adverse Events (AEs)</title>
          <description>An adverse event (AE) is any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
          <population>All participants who received at least one dose of the investigational drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="2"/>
                    <measurement group_id="O4" value="1"/>
                    <measurement group_id="O5" value="2"/>
                    <measurement group_id="O6" value="2"/>
                    <measurement group_id="O7" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants Who Discontinued Study Drug Due To An AE</title>
        <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
        <time_frame>Up to 5 days</time_frame>
        <population>All participants who received at least one dose of the investigational drug.</population>
        <group_list>
          <group group_id="O1">
            <title>Ruzasvir 10 mg - GT3</title>
            <description>Participants with GT3 were administered 10 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O2">
            <title>Ruzasvir 30 mg - GT3</title>
            <description>GT3 participants were administered 30 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O3">
            <title>Ruzasvir 60 mg - GT3</title>
            <description>Participants with GT3 were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O4">
            <title>Ruzasvir 120 mg - GT3</title>
            <description>GT3 participants were administered 120 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O5">
            <title>Ruzasvir 10 mg - GT2b</title>
            <description>GT2b participants were administered 10 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O6">
            <title>Ruzasvir 60 mg - GT2b</title>
            <description>GT2b participants were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
          </group>
          <group group_id="O7">
            <title>Ruzasvir 60 mg - GT1a</title>
            <description>GT1a participants were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days. One participant was later determined to be GT1b.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Discontinued Study Drug Due To An AE</title>
          <description>An AE is any untoward medical occurrence in a participant administered a pharmaceutical product which does not necessarily have to have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product or protocol-specified procedure, whether or not considered related to the medicinal product or protocol-specified procedure. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition that is temporally associated with the use of the Sponsor's product, is also an AE.</description>
          <population>All participants who received at least one dose of the investigational drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="3"/>
                <count group_id="O2" value="3"/>
                <count group_id="O3" value="3"/>
                <count group_id="O4" value="3"/>
                <count group_id="O5" value="3"/>
                <count group_id="O6" value="3"/>
                <count group_id="O7" value="4"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                    <measurement group_id="O4" value="0"/>
                    <measurement group_id="O5" value="0"/>
                    <measurement group_id="O6" value="0"/>
                    <measurement group_id="O7" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Up to 61 days</time_frame>
      <desc>The population analyzed is all participants who received at least one dose of the investigational drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ruzasvir 10 mg - GT3</title>
          <description>GT3 participants were administered 10 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="E2">
          <title>Ruzasvir 30 mg - GT3</title>
          <description>GT3 participants were administered 30 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="E3">
          <title>Ruzasvir 60 mg - GT3</title>
          <description>GT3 participants were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="E4">
          <title>Ruzasvir 120 mg - GT3</title>
          <description>GT3 participants were administered 120 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="E5">
          <title>Ruzasvir 10 mg - GT2b</title>
          <description>GT2b participants were administered 10 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="E6">
          <title>Ruzasvir 60 mg - GT2b</title>
          <description>GT2b participants were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days.</description>
        </group>
        <group group_id="E7">
          <title>Ruzasvir 60 mg - GT1a</title>
          <description>GT1a participants were administered 60 mg Ruzasvir in capsule form, orally, once per day for 5 days. One participant was later determined to be GT1b.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E6" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E7" subjects_affected="2" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Catheter site phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Feeling hot</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="2" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Restlessness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="3"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="3"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="4"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The Sponsor must have the opportunity to review all proposed abstracts, manuscripts or presentations regarding this trial 45 days prior to submission for publication/presentation. Any information identified by the Sponsor as confidential must be deleted prior to submission; this confidentiality does not include efficacy and safety results.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

